Disruptive MedTech ideas attract investment, but they are high-risk. Founders should de-risk these big bets by developing market access and commercial strategies simultaneously with product development, not after FDA approval.
Companies often focus commercial efforts on major urban and academic hospitals. However, the actual disease burden and patient populations are often concentrated in rural areas, representing significant untapped demand for medical technology.
Historically, MedTech sales success depended on personal relationships built over decades. AcuityMD's founder realized that synthesizing disparate public data provides deep customer insights, allowing new innovators to compete without an established network.
Gaining FDA approval is not the finish line. Many innovative devices fail because they lack a clear reimbursement strategy. Founders must build the economic case for payers and providers in concert with their clinical and regulatory strategy from day one.
As doctors integrate AI into their work (e.g., ambient scribing), they expect more from their partners. MedTech sales reps can no longer rely solely on relationships; they must provide data-backed, highly personalized insights to be valuable.
Standard sales software can't handle MedTech's unique relationships, like a surgeon working at multiple hospitals under different contracts. Success requires building a specific "ontology" that maps these complex, non-linear interactions.
Field sales reps won't adopt complex data tools. The key is automating their prep work. AcuityMD's one-click "call plan" synthesizes all relevant data into an immediately useful brief, bridging the critical gap between data and action.
The next wave of MedTech innovation won't just come from engineers. It will come from creating tools that allow surgeons and clinicians—those who see problems firsthand—to easily prototype and de-risk new device concepts, vastly expanding the market for innovation itself.